[1]薛祚臣 程爱娟.心房颤动合并肿瘤患者的治疗现状及进展[J].心血管病学进展,2021,(9):773-775.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
　XUE Zuochen,CHENG Aijuan.Status and Progress of Treatment in Patients with Atrial Fibrillation and Tumor[J].Advances in Cardiovascular Diseases,2021,(9):773-775.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]

点击复制

心房颤动合并肿瘤患者的治疗现状及进展()

分享到：

参考文献/References:

[1］ Camm AJ , Lip GY , de Caterina R , et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation — Developed with the special contribution of the European Heart Rhythm Association [J]. Eur Heart J , 2012 , 33 ( 21 ): 2719 - 2747 .

[2］O’Neal WT,Lakoski SG,Qureshi W,et al. Relation between cancer and atrial fibrillation(from the R E asons for G eographic A nd R acial D ifferences in S troke S tudy) [J] . Am J Cardiol , 2015 , 115(8):1090 - 1094.

[3］ Lateef N,Kapoor V,Ahsan MJ, et al. Atrial fibrillation and cancer;understanding the mysterious relationship through a systematic review[J]. J Community Hosp Intern Med Perspect , 2020, 10(2):127-132.

undefined[4] undefinedCollette KM,Zhou XD,Amoth HM,et al. Long-term α1B-adrenergic receptor activation shortens lifespan,while α1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence[J]. Age(Dordr)2014,36(4):9675.

undefined[5] undefinedCoumel P. Paroxysmal atrial fibrillation:a disorder of autonomic tone?[J]. Eur Heart J,1994,15 Suppl A:9-16.

undefined[6] undefinedHu YF,Chen YJ,Lin YJ,et al. Inflammation and the pathogenesis of atrial fibrillation[J]. Nat Rev Cardiol,2015,12(4):230-243.

undefined[7] undefinedAllin KH,Nordestgaard BG. Elevated C-reactive protein in the diagnosis,prognosis,and cause of cancer[J]．Crit Rev Clin Lab Sci,2011,48(4):155-170．

undefined[8] undefinedConroy H,Mawhinney L,Donnelly SC. Inflammation and cancer:macrophage migration inhibitory factor(MIF)—The potential missing link[J]. QJM,2010,103(11):831-836.

undefined[9] undefinedKirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace,2016,18(11):1609-1678.

undefined[10] undefinedWilliams B,Mancia G,Spieringet W,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension:The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension:The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension[J]. J Hypertens,2018,36(10):1953-2041.

undefined[11] undefinedMoriyama S,Yokoyama T,Irie K,et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil[J]. J Cardiol Cases,2019,20(5):183-186.

undefined[12] undefinedDeng Y,Tong Y,Deng Y,et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation:a systematic review and metanalysis[J]. J Am Heart Assoc,2019,8(14):e012540.

undefined[13] undefinedSteffel J,Verhamme P,Potpara TS,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Eur Heart J,2018,39(16):1330-1393.

undefined[14] undefinedKlerk CP,Smorenburg SM,Otten HM,et al.The effect of low molecular weight heparin on survival in patient with advanced malignancy[J].J Clin Oncol,2005,23(10):2130-2135.

undefined[15] undefinedPrandoni P, Lensing AW, Piccioli A,et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis[J]. Blood,2002,100(10):3484-3488.

undefined[16] undefinedChen ST,Hellkamp AS,Becker RC,et al. Efficacy and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and a history of cancer:observations from ROCKET AF[J]. Eur Heart J Qual Care Clin Outcomes,2018,5(2):145-152

undefined[17] undefinedFanola CL,Ruff CT,Murphy SA,et al. Effificacy and safety of

edoxaban in patients with active malignancy and atrial fibrillation:analysis of the ENGAGE AF-TIMI 48 trial[J]. J Am Heart Assoc,2018,7(16):e008987

undefined[18] undefinedLópez-Fernández T,Martín-García A,Roldán Rabadán I,et al. Atrial fibrillation in active cancer patients:expert position paper and recommendations[J]. Rev Esp Cardiol,2019,72(9):749-759.

undefined[19] undefinedGiustozzi M,Ali H,Reboldi G,et al. Safety of catheter ablation of atrial fibrillation in cancer survivors[J]. J Interv Card Electrophysiol,2021,60(3):419-426.

undefined[20] undefinedToale C,Jones J,Fitzmaurice GJ,et al. Left atrial appendage clipping as an adjunctive therapy in lung cancer surgery for patients with atrial fibrillation:a case report[J].J Surg Case Rep,2019,2019(11):rjz298.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(9):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(9):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(9):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(9):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(9):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]漆峰林 王恩润 肖骅.心房颤动合并肿瘤治疗管理的双向影响现状[J].心血管病学进展,2024,(9):826.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.013]
　QI Fenglin,WANG Enrun,XIAO Hua.Current Status of Bidirectional Effects of Therapeutic Management of Atrial Fibrillation Combined with Neoplasm[J].Advances in Cardiovascular Diseases,2024,(9):826.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.013]